Mereo Biopharma Group Plc ADR Dossier
Qualitative Analysis
Business overview
Mereo BioPharma Group plc is a clinical-stage biotechnology company developing therapies for rare diseases. Its partnership-led model emphasizes licensing, milestone payments and royalties rather than direct product sales. The principal programs are setrusumab for osteogenesis imperfecta, alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease and out-licensed vantictumab for Autosomal Dominant Osteopetrosis Type 2. Ultragenyx funds global setrusumab development and holds rights in licensed territories, while Mereo retains rights in the EU and UK. Alvelestat is ready for Phase 3 development but requires a partner, and āshibio is responsible for advancing vantictumab. This structure limits direct development commitments but makes progress dependent on clinical outcomes, regulatory decisions and collaborators. Sources: 0001193125-26-115226#business_analysis.business_model; 0001193125-26-343533#business_analysis.innovation_and_rd
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing resources on core rare disease programs (setrusumab and alvelestat) while implementing strategic cost reductions, delaying European pre-commercial and manufacturing investments for setrusumab, and out-licensing non-core assets to extend the cash runway into mid-2027.
Expected impact: Extends the operational runway to clear key clinical and regulatory inflection points without immediate dilutive financing.
Engaging with the FDA and EMA in collaboration with partner Ultragenyx to determine a pediatric regulatory approval path for setrusumab in osteogenesis imperfecta, leveraging strong secondary endpoints (bone mineral density, vertebral fracture reductions, and patient-reported outcomes) despite missing primary fracture-rate endpoints.
Expected impact: Establishes a potential registration pathway for the first approved therapy specifically targeting osteogenesis imperfecta.
Actively negotiating with potential biopharmaceutical partners to secure a licensing or co-development transaction for the Phase 3 development and commercialization of alvelestat in AATD-LD, following alignment with the FDA and EMA on a single 220-patient pivotal trial design.
Expected impact: Secures non-dilutive capital, upfront milestones, and a fully funded pathway to regulatory submission in the US and Europe.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Ultragenyx leads and funds global development of setrusumab (UX143) for osteogenesis imperfecta. Mereo retains commercial rights in the EU and UK, while Ultragenyx holds rights in the US and rest of the world.
Terms: Mereo is eligible to receive up to $245 million in potential milestone payments, plus double-digit royalties on commercial sales in Ultragenyx territories. Mereo will pay royalties to Ultragenyx on sales in Europe.
Out-licensed global rights (excluding Europe) for vantictumab (OMP18R5) for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). āshibio is responsible for funding and leading global clinical development.
Terms: āshibio funds the global program. Mereo retains exclusive commercial rights in Europe and is eligible for future milestone and royalty payments on sales in licensed territories.
Out-licensed global rights for leflutrozole (BGS-649), an oral aromatase inhibitor for male infertility.
Terms: Mereo recognized a $0.5 million milestone payment from ReproNovo in 2025 and remains eligible for future development milestones and royalties.